Fidelity Advisor Communication Services Fund (FGHMX US) stock market data APIs
107.5251
0(0%)
as of May 30, 2025
Try our APIs with
free plan!
Fidelity Advisor Communication Services Fund Financial Data Overview
Prev. Close
107.5251
Open
107.5251
High
107.5251
Low
107.5251
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Fidelity Advisor Communication Services Fund data using free add-ons & libraries
End-of-day & Earnings data
Get Fidelity Advisor Communication Services Fund Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get Fidelity Advisor Communication Services Fund End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fidelity Advisor Communication Services Fund News
New
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 22, 2021 –Genmab A/S (Nasdaq:GMAB) announced today that at a board meeting the board decided to grant 15,241 restricted stock units and 16,335 warrant...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 22, 2021 –Genmab A/S (Nasdaq:GMAB) announced today that at a board meeting the board decided to grant 15,241 restricted stock units and 16,335 warrant...
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement Janssen received European approval for DARZALEX® SC (daratumumab and hyaluronidase-fihj)in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of a...
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement Janssen received European approval for DARZALEX® SC (daratumumab and hyaluronidase-fihj)in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
